AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Wealth Dimensions Group Ltd.

Wealth Dimensions Group Ltd. grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 7.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,929 shares of the company’s stock after acquiring an additional 341 shares during the period. Wealth Dimensions Group Ltd.’s holdings in AstraZeneca were worth $334,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Oppenheimer & Co. Inc. lifted its position in shares of AstraZeneca by 1.5% in the 4th quarter. Oppenheimer & Co. Inc. now owns 11,186 shares of the company’s stock worth $758,000 after buying an additional 166 shares during the last quarter. Arete Wealth Advisors LLC lifted its position in shares of AstraZeneca by 11.4% in the 4th quarter. Arete Wealth Advisors LLC now owns 12,222 shares of the company’s stock worth $828,675,870,000 after buying an additional 1,251 shares during the last quarter. Foster Victor Wealth Advisors LLC bought a new position in shares of AstraZeneca in the 4th quarter worth about $239,000. ARGI Investment Services LLC lifted its position in AstraZeneca by 2.6% in the 4th quarter. ARGI Investment Services LLC now owns 7,261 shares of the company’s stock valued at $492,000 after purchasing an additional 187 shares during the last quarter. Finally, Tudor Investment Corp Et Al acquired a new position in AstraZeneca during the 3rd quarter valued at about $5,087,000. 16.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

AZN has been the subject of a number of analyst reports. Morgan Stanley raised shares of AstraZeneca from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, April 11th. StockNews.com started coverage on shares of AstraZeneca in a report on Thursday, May 18th. They issued a “strong-buy” rating on the stock. Finally, Argus dropped their target price on shares of AstraZeneca from $85.00 to $80.00 in a report on Friday. One analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and a consensus target price of $103.00.

AstraZeneca Stock Up 0.9 %

AstraZeneca stock traded up $0.66 during trading hours on Friday, hitting $72.45. The company had a trading volume of 1,821,824 shares, compared to its average volume of 4,639,133. The firm has a market capitalization of $224.57 billion, a P/E ratio of 47.23, a price-to-earnings-growth ratio of 1.45 and a beta of 0.52. The company has a debt-to-equity ratio of 0.75, a current ratio of 0.90 and a quick ratio of 0.70. The firm’s fifty day moving average is $73.83 and its 200-day moving average is $69.02. AstraZeneca PLC has a fifty-two week low of $52.65 and a fifty-two week high of $76.56.

About AstraZeneca

(Get Rating)

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.